← Eichor
Study identifier: NCT00349830 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

Condition: Carcinomas (Including Squamous Cell and Adenocarcinoma) · Neoplasms  ·  Sponsor: Stanford University

PhaseN/A
Planned participants2000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.

This description comes directly from the study's public registry record.

Talk to the study team

gitrialeligibility@stanford.edu gitrialeligibility@stanford.edu  ·  650-498-7757  ·  gitrialeligibility@stanford.edu

gitrialeligibility@stanford.edu  ·  650-498-7757  ·  gitrialeligibility@stanford.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Stanford University School of MedicineStanford, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT00349830